{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:29:22Z","timestamp":1775482162179,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Common Infrastructures program of the Vision Health Research Network"},{"name":"Vice-Dean of Research and Development of the Universit\u00e9 de Montr\u00e9al"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>This study reports three cases of toxoplasmosis retinochoroiditis following coronavirus disease 2019 (COVID-19) infection or vaccination from the national Canadian COVID-19 Eye Registry between December 2020 and September 2021. A 56-year-old male presented 15 days after a positive COVID-19 test with toxoplasmosis retinochoroiditis. He later relapsed 8 days following a first Pfizer-BioNTech vaccine dose. Two patients presented with toxoplasmosis retinochoroiditis following COVID-19 vaccination: A 58-year-old female presenting 4 days following a first Pfizer-BioNTech vaccine dose with anterior uveitis and a posterior pole lesion discovered 3 months later and a 39-year-old female presenting 17 days after a first Moderna vaccine dose. Resolution was achieved with oral clindamycin, oral trimethoprim\/sulfamethoxazole, and topical prednisolone acetate 1%. Patients were offered prophylactic trimethoprim\/sulfamethoxazole for subsequent doses without relapse. Following COVID-19 infection or vaccination, patients may be at risk for toxoplasmosis retinochoroiditis. Prophylactic antibiotics for future doses may be offered to patients with known ocular toxoplasmosis to prevent recurrence.<\/jats:p>","DOI":"10.3390\/vaccines10101692","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T06:13:27Z","timestamp":1665468807000},"page":"1692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recurrent and De Novo Toxoplasmosis Retinochoroiditis following Coronavirus Disease 2019 Infection or Vaccination"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-4362","authenticated-orcid":false,"given":"M\u00e9lanie","family":"H\u00e9bert","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Universit\u00e9 Laval, Quebec, QC G1V 0A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumaya","family":"Bouhout","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Vadboncoeur","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Ophthalmology Department, Centre Universitaire d\u2019Ophtalmologie (CUO), Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al\u2014H\u00f4pital Maisonneuve-Rosemont, Montreal, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0392-3110","authenticated-orcid":false,"given":"Marie-Jos\u00e9e","family":"Aubin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Ophthalmology Department, Centre Universitaire d\u2019Ophtalmologie (CUO), Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux de l\u2019Est-de-l\u2019\u00cele-de-Montr\u00e9al\u2014H\u00f4pital Maisonneuve-Rosemont, Montreal, QC H1T 2M4, Canada"},{"name":"Department of Social and Preventive Medicine, School of Public Health, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100882","DOI":"10.1016\/j.preteyeres.2020.100882","article-title":"Pathogenesis of ocular toxoplasmosis","volume":"81","author":"Smith","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10792-019-01242-1","article-title":"Chorio-retinal toxoplasmosis: Treatment outcomes, lesion evolution and long-term follow-up in a single tertiary center","volume":"40","author":"Achiron","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3928\/23258160-20161031-10","article-title":"Reactivation of Latent Toxoplasmosis Following Dexamethasone Implant Injection","volume":"47","author":"Olson","year":"2016","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MCG.0000000000000521","article-title":"Ocular Toxoplasmosis Reactivation in a Patient With Inflammatory Bowel Disease Under Treatment With Azathioprine","volume":"50","author":"Puga","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses","volume":"53","author":"Zhou","year":"2020","journal-title":"Immunity"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Majtanova, N., Kriskova, P., Keri, P., Fellner, Z., Majtan, J., and Kolar, P. (2021). Herpes Simplex Keratitis in Patients with SARS-CoV-2 Infection: A Series of Five Cases. Medicina, 57.","DOI":"10.3390\/medicina57050412"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/ijd.15240","article-title":"Herpes zoster ophthalmicus in COVID-19 patients","volume":"59","author":"Nofal","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","volume":"397","author":"Amit","year":"2021","journal-title":"Lancet"},{"key":"ref_12","first-page":"1","article-title":"Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members","volume":"181","author":"Ballin","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/ICL.0000000000000840","article-title":"Bilateral EK Rejection After COVID-19 Vaccine","volume":"47","author":"Abousy","year":"2021","journal-title":"Eye Contact Lens."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12348-021-00260-4","article-title":"Varicella-zoster virus reactivation causing herpes zoster ophthalmicus (HZO) after SARS-CoV-2 vaccination\u2013report of three cases","volume":"11","author":"Papasavvas","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bolletta, E., Iannetta, D., Mastrofilippo, V., De Simone, L., Gozzi, F., Croci, S., Bonacini, M., Belloni, L., Zerbini, A., and Adani, C. (2021). Uveitis and Other Ocular Complications Following COVID-19 Vaccination. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245960"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.jcjo.2020.12.009","article-title":"Data reporting in ophthalmology during COVID-19 pandemic: Need for a Canadian registry","volume":"56","author":"Buys","year":"2021","journal-title":"Can. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-3024.2006.00874.x","article-title":"Ocular toxoplasmosis: In the storm of the eye","volume":"28","author":"Jones","year":"2006","journal-title":"Parasite Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/09273948.2018.1499940","article-title":"Immune Mediators against Toxoplasma Gondii during Reactivation of Toxoplasmic Retinochoroiditis","volume":"27","author":"Rudzinski","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QCO.0000000000000169","article-title":"Toxoplasma prophylaxis in haematopoietic cell transplant recipients: A review of the literature and recommendations","volume":"28","author":"Gajurel","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pradhan, E., Bhandari, S., Gilbert, R.E., and Stanford, M. (2016). Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev., 5.","DOI":"10.1002\/14651858.CD002218.pub2"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ophtha.2012.07.061","article-title":"Interventions for toxoplasma retinochoroiditis: A report by the American Academy of Ophthalmology","volume":"120","author":"Kim","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:49:31Z","timestamp":1760143771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["vaccines10101692"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10101692","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]}}}